drugset / Trial / NCT03069300

N-ACetylcysteine to Reduce Infection and Mortality for Alcoholic Hepatitis

NCT03069300

Phase 3 Unknown 42 enrolled Imperial College London
RandomizedParallel-groupOpen-labelTreatment

Summary

Recent data have suggested that monocyte oxidative burst defect is associated with the development of infection in patients with severe alcoholic hepatitis. One report found reduced 28 day mortality in patients treated with N-acetylcysteine combined with prednisolone when compared to prednisolone alone. The current study seeks to reveal whether the mechanism by which NAC reduces susceptibility to infection is through improvement of phagocyte oxidative burst.

Timeline

Start
2015-10-01
Primary completion
2022-04-01
Completion
2025-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject N-acetylcysteine Small molecule 100 mg/kg Intravenous